Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2015 | Advances in the treatment of CLL at ASCO 2015

Stephan Stilgenbauer • 2 Jun 2015
ASCO 2015
Chronic Lymphocytic Leukemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing chronic lymphocytic leukemia (CLL) treatment landscape. With the development of many new agents, researchers are now investigating how these agents can be optimized in the clinic.

More from Stephan Stilgenbauer

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer • 11 Dec 2023
Acquired mutations associated with resistance to BTKi in patients with CLL
2:52
Acquired mutations associated with resistance to BTKi in patients with CLL
Stephan Stilgenbauer • 11 Dec 2023
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer • 11 Dec 2023
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
2:11
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
Stephan Stilgenbauer • 11 Dec 2023

Related Videos

Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Stephan Stilgenbauer • 6 Dec 2025
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
Stephan Stilgenbauer • 8 Dec 2025
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Stephan Stilgenbauer • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Stephan Stilgenbauer • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals